Rajendra Jangde, Gamal Osman Elhassan, Sulekha Khute, Deependra Singh, Manju Singh, Ram Kumar Sahu, Jiyauddin Khan
Hesperidin is a bioflavonoid constituent that among many other biological activities shows significant wound healing properties. However, the bioavailability of hesperidin when applied topically is limited due to its low solubility and systemic absorption, so novel dosage forms are needed to improve its therapeutic efficacy. The objectives of this study were to develop hesperidin-loaded lipid-polymer hybrid nanoparticles (HLPHNs) to enhance the delivery of hesperidin to endogenous sites in the wound bed and promote the efficacy of hesperidin. HLPHNs were optimized by response surface methodology (RSM) using the Box-Behnken design. HLPHNs were prepared using an emulsion-solvent evaporation method based on a double emulsion of water-in-oil-in-water (w/o/w) followed by freeze-drying to obtain nanoparticles. The prepared formulations were characterized using various evaluation parameters. In addition, the antioxidant activity of HLPHN 4 was investigated in vitro using the DPPH model. Seventeen different HLPHNs were prepared and the HLPHN4 exhibited the best mean particle size distribution, zeta potential, drug release and entrapment efficiency. The values are 91.43 nm, +23 mV, 79.97% and 92.8%, respectively. Transmission electron microscope showed similar spherical morphology as HLPHN4. Differential scanning calorimetry verified the physical stability of the loaded drug in a hybrid system. In vitro release studies showed uniform release of the drug over 24 h. HLPHN4 showed potent antioxidant activity in vitro in the DPPH model. The results of this study suggest that HLPHNs can achieve sustained release of the drug at the wound site and exhibit potent in vitro antioxidant activity.
Int J Mol Med. 2019 Jul;44(1):3-15
[PMID:
31115493]
Curr Drug Deliv. 2011 Nov;8(6):640-60
[PMID:
22313160]
Int J Pharm. 2017 Nov 25;533(1):156-168
[PMID:
28963013]
Int J Nanomedicine. 2013;8:545-54
[PMID:
23431115]
Int J Biol Macromol. 2020 Dec 1;164:356-370
[PMID:
32682976]
Antioxidants (Basel). 2021 Aug 28;10(9):
[PMID:
34573007]
Int J Pharm. 2019 Apr 20;561:274-282
[PMID:
30851393]
Int J Biol Macromol. 2016 Nov;92:892-899
[PMID:
27496605]
Int J Pharm. 2019 Feb 25;557:374-389
[PMID:
30610896]
Antioxidants (Basel). 2018 Jul 24;7(8):
[PMID:
30042332]
Int J Biol Macromol. 2018 Aug;115:1211-1217
[PMID:
29730004]
J Ethnopharmacol. 2018 Dec 5;227:290-299
[PMID:
30121235]
Artif Cells Nanomed Biotechnol. 2016;44(2):635-41
[PMID:
25375215]
Saudi J Biol Sci. 2022 Mar;29(3):1283-1297
[PMID:
35280568]
Int J Biol Macromol. 2019 Oct 15;139:1168-1181
[PMID:
31419553]
Carbohydr Polym. 2016 Oct 20;151:172-188
[PMID:
27474556]
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):378-394
[PMID:
30691314]
Biomater Res. 2016 Oct 31;20:34
[PMID:
27807476]
Eur J Pharm Biopharm. 2008 Jun;69(2):454-65
[PMID:
18359211]
Sci Rep. 2020 Jun 9;10(1):9362
[PMID:
32518242]
EXCLI J. 2018 May 04;17:399-419
[PMID:
29805347]
Pharmaceutics. 2021 Jan 14;13(1):
[PMID:
33466598]
J Clin Med. 2021 Aug 13;10(16):
[PMID:
34441854]
Int J Nanomedicine. 2019 Mar 19;14:1937-1952
[PMID:
30936695]
Nanomedicine. 2016 Jul;12(5):1303-11
[PMID:
26964482]
Artif Cells Nanomed Biotechnol. 2016;44(2):571-80
[PMID:
25363752]
Expert Opin Drug Deliv. 2016;13(5):609-12
[PMID:
26978527]
Chem Commun (Camb). 2012 Jun 14;48(47):5835-7
[PMID:
22555311]
Bioact Mater. 2017 Jul 17;2(4):269-280
[PMID:
29744436]
Reprod Toxicol. 2016 Apr;60:140-7
[PMID:
26923737]
Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1149-56
[PMID:
19473187]
